PIK3CA and acute lymphoblastic leukemia: Taken together, we unveiled a promising treatment combining an asparagine and glutamine degrader with a PI3K signaling inhibitor that should be considered as a therapeutic option in a bridge-to-transplant approach for R/R T-ALL/LL harboring PI3K signaling deregulation.